How to Dose BPC-157 + TB-500

The Body Pharm BPC-157 + TB-500 pen is a single pre-filled cartridge with both peptides co-dissolved together at a fixed 50/50 blend — 16 mg of BPC-157 and 16 mg of TB-500 in the one 3 mL cartridge (32 mg total). There is one dial and one injection: because the two peptides share the cartridge, the number you dial is the dose of each peptide, and the total delivered is double that. Dial 0.25 mg and you give 0.25 mg of BPC-157 plus 0.25 mg of TB-500 (0.5 mg total); dial 1 mg and you give 1 mg of each (2 mg total). A typical research schedule dials 0.5 mg (500 mcg of each) once daily for a four-week loading phase, then steps down to 0.25 mg (250 mcg of each) once daily in maintenance [1][3][7]. This guide covers the phase-by-phase dosing table, the single-pen workflow, and the cold-chain variables that matter for a co-dissolved peptide pen.

This article covers: the baseline daily dosing across loading and maintenance phases; how to read the single co-dissolved pen's dial; and which protocol variables (body weight, injection site, stack duration) require logging to ensure reproducibility.

Key Takeaways

• One pen, one dial, one injection: BPC-157 and TB-500 are co-dissolved 50/50 in a single 3 mL cartridge holding 16 mg of each peptide
• The dialled figure is the dose of each peptide; total delivered is double. Dial 0.5 mg → 500 mcg of each → 1 mg total. Dial 0.25 mg → 250 mcg of each → 0.5 mg total
• Standard schedule: dial 0.5 mg (500 mcg of each) once daily through a four-week loading phase, then 0.25 mg (250 mcg of each) once daily in maintenance
• Because the two are co-dissolved, they are always dosed together in the same fixed ratio — there is no separate schedule or second injection to track
• Neither peptide holds MHRA approval; all supply is positioned for research use only
• Cold-chain discipline (2–8 °C, no freeze-thaw cycles) is as critical as dosing accuracy

Quick-reference baseline

Because the peptides are co-dissolved 50/50, they are always delivered in equal amounts from the one dial. Both remain unlicensed by the MHRA and sit outside any approved indication [5][6].

Research Disclaimer

All Body Pharm UK products are sold strictly for research and analytical purposes only. Not for human consumption.

The protocols and dosing tables throughout this guide describe published and practitioner-reported parameters for in vitro and analytical research contexts. BPC-157 and TB-500 are unlicensed in the UK and hold no MHRA-approved indication or dosing standard [5][6]. Nothing here constitutes medical advice. For mechanistic background, see our BPC-157 vs TB-500 compared reference, or browse the recovery peptide category.

What Are BPC-157 and TB-500?

BPC-157 is a synthetic 15-amino-acid sequence derived from a fragment of body protection compound identified in human gastric juice. It is investigated in pre-clinical models for angiogenic signalling, tendon-to-bone interface effects, and gut-barrier modulation. TB-500 is a synthetic analogue covering the active region of Thymosin Beta-4 (TB-4), a 43-amino-acid peptide studied for actin regulation, cell migration, and cardiac and dermal wound-healing models.

The two are studied together because their proposed mechanisms operate on different spatial scales: BPC-157 acts locally at the injection or injury site, while TB-500 distributes systemically. That complementarity, not redundancy, is the usual rationale for combining them in research protocols [5][7].

The bulk of the mechanistic literature for BPC-157 comes from Sikiric and colleagues across multiple pre-2024 rodent studies [3][8]. Pre-2024 pharmacokinetic work in animals describes TB-500's plasma half-life on the order of hours; downstream gene-expression effects are thought to outlast circulating peptide, which is why a steady once-daily schedule is used to sustain exposure [5][7]. Readers wanting newer human data should note that no high-quality 2024–2025 peer-reviewed dosing trials had appeared in major databases at the time of writing [3][9].

For the side-by-side mechanism table, receptor targets and tissue tropism, see BPC-157 vs TB-500 compared. Broader stack options sit in the recovery peptide category.

Why Combine BPC-157 with TB-500?

The research rationale rests on spatial complementarity: BPC-157 operates as a local tissue-repair signal, while TB-500 operates as a systemic cell-migration and remodelling signal. The combination addresses the injury site and the surrounding repair environment in parallel [6][8]. This is a mechanistic hypothesis extrapolated from separate pre-clinical work, not a proven clinical outcome. No peer-reviewed trial has tested the two peptides administered together as of 2026.

BPC-157's pre-2020 rodent literature centres on angiogenesis, growth-factor upregulation, and tendon-to-bone interface effects at or near the site of administration [3]. TB-500, as a synthetic analogue of the active region of TB-4, appears in earlier animal models for actin regulation and cell migration that operate systemically once the peptide distributes via plasma [5][7]. One peptide drives the local repair cascade; the other supports the broader cellular machinery that repair depends on [6][9].

Local vs systemic action at a glance

For the deeper receptor-level breakdown, see BPC-157 vs TB-500 compared. Adjacent compounds sit in the recovery peptide category.

BPC-157 + TB-500 Dosing Protocol at a Glance

The protocol splits into a four-week loading phase and an open-ended maintenance phase. Because both peptides are co-dissolved in one cartridge, a single dial setting doses both at once, always in a 50/50 ratio. Only the dial figure steps down between phases. All figures are extrapolated from pre-2024 practitioner literature [5][7][9] and rodent pharmacokinetic work. No MHRA-approved dosing exists for either peptide in the UK [3].

"Daily" here means seven days per week, not weekday-only. Both peptides have plasma half-lives reported in hours in pre-2020 animal work, so continuous once-daily exposure is the convention used to drive cumulative tissue effects [5][9].

Reading the dial: dialled figure = dose of each peptide

This is the single most important point about the pen. The two peptides share the cartridge at a fixed 50/50 blend, so the number on the dial is the amount of each peptide, and the total you inject is double that figure:

• Dial 0.25 mg → 0.25 mg BPC-157 + 0.25 mg TB-500 = 0.5 mg total
• Dial 0.5 mg → 0.5 mg (500 mcg) of each = 1 mg total
• Dial 1 mg → 1 mg of each = 2 mg total

You never dial BPC-157 and TB-500 separately — there is one dial and one injection. In the loading phase you dial 0.5 mg (500 mcg of each); in maintenance you dial 0.25 mg (250 mcg of each). BPC-157's proposed local angiogenic signalling and TB-500's systemic cell-migration effects both benefit from repeated, near-continuous exposure, so a single shared daily dose keeps the stack simple and reproducible [5][7][9].

The numbers are best treated as a starting reference, not a fixed prescription. The underlying citations are 2023 clinical summaries and practitioner guides [5][7][9]. For the mechanistic background these figures rest on, see BPC-157 vs TB-500 compared. For adjacent compounds, the recovery peptide category lists what UK research suppliers currently stock.

Loading Phase (Weeks 1–4): Doses Explained

The loading phase dials 0.5 mg once daily, delivering 500 mcg of each peptide (1 mg total). Front-loading at the higher end of the range for the first four weeks reflects the practitioner convention of building tissue-level effect early, then holding a lower daily dose once the acute window closes [5][7][9].

500 mcg of BPC-157 sits at the upper end of the 250–500 mcg range described across pre-2024 practitioner protocols; the figure also appears in human-adjacent clinical discussions where 150–375 mcg twice daily is described as body-size-adjusted [9]. Because TB-500 is co-dissolved in the same cartridge at the same concentration, it is delivered in the identical amount from the one dial [7]. Both figures derive from pre-2024 literature and should be treated as potentially stale until newer controlled data appears.

No efficacy claims follow from these numbers alone; they describe exposure, not outcome. For mechanistic context on why both peptides run simultaneously, see BPC-157 vs TB-500 compared.

Maintenance Phase (Weeks 5+): Stepping the Dial Down

After loading, the dial drops from 0.5 mg to 0.25 mg once daily — delivering 250 mcg of each peptide (0.5 mg total). The lower maintenance dose reflects the working assumption in pre-2024 practitioner literature that once tissue-level effects are established, a smaller continuous daily dose sustains them [7][9].

Total protocol duration varies in the source material. Practitioner summaries describe 4–6 week loading blocks followed by extended maintenance, while combination-stack discussions reference 8–12 week total runs before a wash-out [7][9][10]. No 2024–2025 controlled trial defines an optimal stop point, so duration is a practitioner choice rather than an evidence-based endpoint [7].

Two practical notes on the step-down. First, the 0.25 mg maintenance figure is convention, not a pharmacokinetically validated dose — it is simply the conservative end of the practitioner range. Second, because the peptides are co-dissolved, whatever figure you dial always applies to both equally; there is no way to run them at different amounts. For adjacent compounds during or after the wash-out, see the recovery peptide category.

Administration: Subcutaneous Injection Guide

Subcutaneous injection at a 45° angle into a pinched fold of abdominal or flank tissue is the standard delivery route reported for the BPC-157 + TB-500 pen. The single co-dissolved cartridge removes the need to draw or mix from separate vials at the point of use.

Site selection follows two logics. For systemic effect, abdominal or flank tissue offers consistent absorption and easy site rotation. Where the research interest is a specific tendon, joint or muscle, BPC-157 literature has examined proximity-of-injection as a variable — localised subcutaneous administration near the target tissue is used in some rodent tendon and ligament models [6][7]. Because the pen co-doses both peptides in one shot, a site chosen for local BPC-157 effect also delivers the TB-500 component, which acts systemically regardless [7][9].

Because the pen is dosed daily, reported protocols rotate sites between injections — at least 2–3 cm apart, avoiding repeating the same spot on consecutive days — which limits lipohypertrophy and local irritation. The BPC-157 vs TB-500 compared guide covers the localised-versus-systemic distinction in more depth.

The Body Pharm Pen

The Body Pharm UK BPC-157 + TB-500 pen (2026) is a single pre-filled device holding both peptides co-dissolved together at a fixed 50/50 ratio in one 3 mL cartridge (16 mg of each). It removes the need to reconstitute, mix, or draw from two vials at the point of injection. One dial sets the dose; the figure dialled is the amount of each peptide, and the two are always delivered together in equal measure.

Reported administration sequence:

1. Temperature equilibration. Protocols describe removing the pen from the fridge (2–8 °C) and allowing it to reach room temperature for 15–20 minutes. Cold solution injected straight from refrigeration is reported to sting and can transiently affect bioavailability at the depot site.
2. Needle attachment. A fresh single-use pen needle is attached and the seal discarded.
3. Priming. The pen is primed with a small test dial until a bead forms at the needle tip, clearing air from the line.
4. Dose dialling. The phase-appropriate figure is dialled — 0.5 mg in loading, 0.25 mg in maintenance. Remember the dialled figure is the amount of each peptide; the total delivered is double.
5. Injection. Subcutaneous administration at 45° into a prepped, dry site is described in the literature.
6. Hold time. Protocols report holding the needle in place for 5–10 seconds after full plunger depression, allowing the depot to settle and preventing track leakage.
7. Aftercare and logging. The reported sequence closes with recapping, logging the daily dose, and returning the pen to refrigeration within 30 minutes of use.

The pre-filled co-dissolved format removes two common error modes seen with separate-vial workflows: cross-contamination between stoppers, and arithmetic mistakes when converting mg/mL concentrations into syringe units. For the rationale behind running both peptides together rather than alone, see BPC-157 vs TB-500 compared.

Aseptic technique checklist

Readers stocking adjacent compounds can browse the recovery peptide category.

Storage

Store the pen at 2–8 °C, protected from light, and never freeze it. The pen ships pre-filled and co-dissolved, so no end-user reconstitution is required. Peptide degradation accelerates with heat exposure, UV light, and repeated freeze-thaw cycles. Cold-chain storage discipline matters as much as dosing accuracy. A single freeze-thaw cycle is enough to compromise integrity.

Unopened, the pen keeps for 24 months at 2–8 °C. Once first pierced (first use), use it within 12 months. If refrigeration isn't available the pen stays stable at room temperature (up to 30 °C) for up to 30 days. At 0.5 mg per day in loading, a 16 mg-of-each cartridge holds roughly a month of loading-phase doses. BPC-157 and TB-500 remain unlicensed research compounds in the UK with no MHRA-approved stability data [8][9]. If a pen has been above 30 °C, or shows any cloudiness or particulate matter, discard it rather than dose-adjust around suspected degradation.

For background on why these two peptides are paired in the first place, the BPC-157 vs TB-500 comparison covers the mechanistic split. The broader recovery peptide category lists adjacent compounds with comparable cold-chain requirements.

Key Variables That Affect the Research Protocol

Five variables move a BPC-157 + TB-500 protocol from generic to specific: body weight scaling, administration timing, injection-site proximity, stack duration, and concurrent compounds. None are addressed by an MHRA-approved dosing standard, because no such standard exists for either peptide as of 2026 [5][6].

Body weight scaling and mcg/kg dosing

Some rodent BPC-157 studies use a 10 mcg/kg reference dose [unverified, pre-2020 animal data]. The flat 250–500 mcg human range cited in 2023 clinical summaries is a simplified working figure rather than a validated mcg/kg dosing curve. No 2024–2025 trial has defined a precise weight-based human dose [1][9]. A 90 kg researcher and a 60 kg researcher using the same flat daily dial are not running the same protocol on a mcg/kg basis. This variable is commonly logged to allow comparison across future studies.

Administration timing relative to feeding

BPC-157 has been studied on an empty stomach in rodent gastric models [unverified, pre-2020]. Whether that timing affects subcutaneous absorption in humans is not characterised in the 2023–2025 literature. Because the pen is dosed daily, researchers often fix a consistent time of day; fasted versus fed administration is a logged variable rather than a settled answer.

Injection-site proximity

Localised (near the target tissue) versus systemic subcutaneous administration of BPC-157 produces different outcomes in animal tendon and gastric models [unverified, pre-2020]. TB-500 acts systemically regardless, given its mechanism involves circulating TB-4 activity [3][7]. Because the pen co-doses both, a site chosen for local BPC-157 effect is typically recorded as a variable alongside the systemic TB-500 exposure it also delivers.

Stack duration

Published practitioner protocols run 4–12 weeks, with 4–6 weeks the most common loading window [2][7][9]. Continuous use beyond 12 weeks is not characterised in the available literature. The BPC-157 vs TB-500 comparison covers the mechanistic case for cycling rather than running indefinitely.

Concurrent compounds

Interactions between BPC-157, TB-500 and other peptides are not formally studied. The GHK-Cu pairing sometimes referenced in US clinic content is descriptive, not trial-backed [8]. Readers cross-referencing the recovery peptide category should treat any multi-peptide combination as an uncharacterised variable rather than an additive certainty.

Frequently Asked Questions

Are BPC-157 and TB-500 dosed at the same amount?

Yes — by construction. They are co-dissolved 50/50 in one cartridge, so a single dial setting delivers the same amount of each. Dial 0.5 mg and you give 500 mcg of each (1 mg total); dial 0.25 mg and you give 250 mcg of each (0.5 mg total). There is no separate schedule or unit system to track for each peptide.

Does the dial figure mean the total dose or the dose of each peptide?

It is the dose of each peptide. Because both are in the cartridge together at a 50/50 blend, the total you inject is double the dialled figure. Dial 1 mg and you deliver 1 mg of BPC-157 plus 1 mg of TB-500, 2 mg in total.

How often is the pen injected?

Once daily, every day, through loading and maintenance alike. Older practitioner material sometimes described less-frequent TB-500 dosing; the co-dissolved pen instead runs a steady daily dose for both, which keeps cumulative exposure simple and identical across the stack [5][7].

How long does a typical BPC-157 + TB-500 research cycle last?

Published practitioner protocols run 4–12 weeks, with 4–6 weeks the most common loading window [2][7][9]. Continuous use beyond 12 weeks is not characterised in the available literature. Cycling rationale is covered in the BPC-157 vs TB-500 compared guide.

Does the pen need to be refrigerated?

Store it at 2–8 °C. Unopened it keeps for 24 months; once first used, use it within 12 months. If refrigeration isn't available it stays stable at room temperature (up to 30 °C) for up to 30 days. Do not freeze it.

Can the same pen be used for both loading and maintenance phases?

Yes. The same pen covers both phases — you simply dial a smaller figure in maintenance (0.25 mg instead of 0.5 mg). The device is re-dialled to the lower setting, not refilled.

Is there a research rationale for injecting near the area of interest vs a neutral site?

For BPC-157, localised versus systemic subcutaneous administration produces different outcomes in animal tendon and gastric models [unverified, pre-2020]. TB-500 acts systemically regardless [3], and the pen delivers both from one injection. Readers comparing options across the recovery peptide category should log site choice as a protocol variable.

What does the pen cost?

The Body Pharm UK BPC-157 + TB-500 pen (2026) retails at £110 per unit. The pre-filled, co-dissolved cartridge removes the reconstitution and dose-conversion error modes of a separate-vial workflow.

Where to Source BPC-157 + TB-500 in the UK

UK researchers can obtain BPC-157 and TB-500 from domestic peptide suppliers that label both compounds as research-only, reflecting their unlicensed status with the MHRA [6][7]. Body Pharm UK supplies BPC-157 + TB-500 as a single pre-filled research pen with both peptides co-dissolved at a fixed 50/50 ratio, at £110 per unit. This removes the reconstitution-asymmetry variables flagged earlier in this guide.

Neither peptide holds MHRA marketing authorisation, so all supply is positioned for laboratory research rather than human administration [6][7].

Next Steps

Revisit the BPC-157 vs TB-500 compared guide to confirm the mechanistic background this protocol assumes, then browse the recovery peptide category for adjacent compounds. Research logs commonly record body weight, injection sites, administration timing, and concurrent compounds before a research order is placed. That record supports refining the approach across future cycles and contributes to the evidence base for these compounds.

References

1. Practitioner-reported BPC-157 dosing ranges and daily maintenance conventions (research-community summaries, pre-2024). No single peer-reviewed primary source; unverified.
2. Practitioner BPC-157 loading-phase protocols (250–500 mcg daily, 4–6 weeks; 150–375 mcg twice-daily figures from 2023 clinical summaries). No single peer-reviewed primary source; unverified.
3. Krivic A, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006. pubmed.ncbi.nlm.nih.gov/16583442
4. Practitioner TB-500 maintenance-dosing conventions (continuous daily dosing at a reduced amount). No single peer-reviewed primary source; unverified.
5. General regulatory and mechanistic framing (BPC-157/TB-500 unlicensed by the MHRA; systemic Tβ4 distribution). Composite of regulatory and review material; no single primary source; unverified.
6. General regulatory and handling framing (unlicensed MHRA status; co-dissolved pen format; localised BPC-157 tendon-model administration). Composite descriptive note; no single primary source; unverified.
7. Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. pubmed.ncbi.nlm.nih.gov/22074294
8. Clinic and vendor handling guidance (Certificate of Analysis practice; GHK-Cu pairing commentary). Descriptive; no single peer-reviewed primary source; unverified.
9. Clinical-summary and vendor discussions of BPC-157 500 mcg / body-size-adjusted dosing and peptide stability (2023). No single peer-reviewed primary source; unverified.
10. Swolverine 2023 practitioner summary and combination-stack discussions (loading blocks, 8–12 week total runs). Vendor/practitioner content; no peer-reviewed primary source; unverified.